KLK3 and posterior cortical atrophy: Current prognostic tools at initial diagnosis of PCa (e.g. PSA, Gleason) are sub-optimal for risk stratification and cannot clearly distinguish aggressive from indolent PCa cases, or are cost-prohibitive in the routine clinical setting (e.g. whole genome (WGS) and whole exome (WES) sequencing).